$1.81
1.69% today
Nasdaq, Feb 05, 04:21 pm CET
ISIN
US29479A1088
Symbol
ERAS
Sector
Industry

Erasca Inc Stock price

$1.78
-0.89 33.33% 1M
-0.77 30.06% 6M
-0.73 29.08% YTD
+0.08 4.71% 1Y
-9.67 84.45% 3Y
-15.65 89.79% 5Y
-15.65 89.79% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+0.02 1.14%
ISIN
US29479A1088
Symbol
ERAS
Sector
Industry

Key metrics

Market capitalization $503.25m
Enterprise Value $237.28m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.12
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-155.25m
Free Cash Flow (TTM) Free Cash Flow $-109.78m
Cash position $318.91m
EPS (TTM) EPS $-0.83
P/E forward negative
Short interest 13.32%
Show more

Is Erasca Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Erasca Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Erasca Inc forecast:

8x Buy
100%

Analyst Opinions

8 Analysts have issued a Erasca Inc forecast:

Buy
100%

Financial data from Erasca Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 3.88 3.88
4% 4%
-
-3.88 -3.88
4% 4%
-
- Selling and Administrative Expenses 33 33
12% 12%
-
- Research and Development Expense 114 114
45% 45%
-
-151 -151
37% 37%
-
- Depreciation and Amortization 3.88 3.88
4% 4%
-
EBIT (Operating Income) EBIT -155 -155
37% 37%
-
Net Profit -159 -159
31% 31%
-

In millions USD.

Don't miss a Thing! We will send you all news about Erasca Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Erasca Inc Stock News

Neutral
GlobeNewsWire
5 days ago
SAN DIEGO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Guggenheim Securities SMID Cap Biotech Conference being held at the Lotte New York Palace in New York, New Yor...
Positive
Seeking Alpha
9 days ago
Naporafenib is Erasca's main candidate, and it has Fast Track status for NRASm melanoma. I see the company has a robust balance sheet, with roughly $463.3 million in cash and equivalents as of Q3, 2024. They estimate a runway into 2H2027. SEACRAFT-1 already showed that Naporafenib has potentially better efficacy compared to the SoC and competitors.
Neutral
GlobeNewsWire
3 months ago
Positive preliminary Phase 1b data in SEACRAFT-1 NRASm melanoma cohort bolsters conviction in ongoing SEACRAFT-2 registrational trial; Stage 1 randomized data expected in 2025
More Erasca Inc News

Company Profile

Erasca, Inc. is a clinical stage precision oncology company that focuses on discovering, developing, and commercializing therapies for RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim on July 2, 2018 and is headquartered in San Diego, CA.

Head office United States
CEO Jonathan Lim
Employees 126
Founded 2018
Website www.erasca.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today